Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.64 |
| ▸ | MAOA | P21397 | 11/20 | 0.64 |
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803144 | 0.86 | MAOB (0.66) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL803206 | 0.82 | MAOB (0.58) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL4549094 | 0.79 | MAOB (0.52) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL30777896 | 0.77 | MAOB (0.62) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL30777900 | 0.75 | MAOB (0.54) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL30768919 | 0.75 | MAOB (0.64) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL281588 | 0.75 | MAOB (1.00) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL17954215 | 0.75 | MAOB (0.48) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL2329488 | 0.73 | MAOB (0.64) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL4549090 | 0.73 | MAOB (0.47) | MAOBMAOAGRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096795-B2 | Liquid crystal display | MERCK PATENT GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | LPXN, VCL, ACP3 | MAOB 2889/4885MAOA 2468/4885GRM5 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.